Source:http://linkedlifedata.com/resource/pubmed/id/15899781
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2005-5-18
|
pubmed:abstractText |
We studied HER-2/neu (HER-2) and topoisomerase IIa (topo2a) amplification (using chromogenic in situ hybridization) and overexpression (immunohistochemical analysis) in 113 invasive breast carcinomas. A gene copy number/chromosome 17 copy number ratio of 2.0 or higher indicated amplification. A topo2a/chromosome 17 ratio of less than 0.8 indicated gene deletion. HER-2 overexpression was scored according to standard HercepTest guidelines (DAKO, Carpinteria, CA). Overexpression of topo2a was identified when nuclear staining was found in more than 5% of tumor cells. Of 113 tumors, 104 were analyzed successfully for HER-2 and topo2a amplification. Of the 104, 64 showed HER-2 amplification; 25 of these (39%) also showed topo2a amplification. No amplification was found in 40 tumors. Deletion of topo2a was seen in 7 (11%) of 64 HER-2-amplified tumors and 2 (5%) of 40 nonamplified tumors. Of 25 tumors with topo2a amplification, 18 (72%) overexpressed topo2a. Only 3 (4%) of 79 tumors without topo2a amplification overexpressed topo2a. Amplification of topo2a is associated with HER-2 amplification but not vice versa. Amplification of topo2a resulted in protein overexpression in 72% of tumors, but topo2a overexpression rarely occurred without gene amplification. Identification of topo2a and HER-2 status might have therapeutic and prognostic implications.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Topoisomerases, Type II,
http://linkedlifedata.com/resource/pubmed/chemical/DNA topoisomerase II alpha,
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0002-9173
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
123
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
889-95
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:15899781-Antigens, Neoplasm,
pubmed-meshheading:15899781-Breast Neoplasms,
pubmed-meshheading:15899781-DNA Topoisomerases, Type II,
pubmed-meshheading:15899781-DNA-Binding Proteins,
pubmed-meshheading:15899781-Female,
pubmed-meshheading:15899781-Gene Amplification,
pubmed-meshheading:15899781-Humans,
pubmed-meshheading:15899781-Immunohistochemistry,
pubmed-meshheading:15899781-In Situ Hybridization,
pubmed-meshheading:15899781-Prognosis,
pubmed-meshheading:15899781-Receptor, erbB-2,
pubmed-meshheading:15899781-Tumor Markers, Biological
|
pubmed:year |
2005
|
pubmed:articleTitle |
HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses.
|
pubmed:affiliation |
Department of Pathology, Memorial Sloan-Kettering, Cancer Center, New York, NY 10021, USA.
|
pubmed:publicationType |
Journal Article
|